Trial Profile
Randomized,Controlled,Multicenter Study of Autologous Tumor Lysate-pulsed Dendritic and Cytokine-induced Killer Cells(Ag-D-CIK) Combined With Chemotherapy for Gastric Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell activated cytokine-induced killer cells-Shenzhen Hornetcorn (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HYK-Gastric-Cancer
- Sponsors Shenzhen Hornetcorn Biotechnology
- 07 Jun 2015 Planned End Date changed from 1 Nov 2017 to 1 May 2018 as reported by ClinicalTrials.gov.
- 07 Jun 2015 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018 as reported by ClinicalTrials.gov.
- 07 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.